Trius Therapeutics (TSRX) Prices 8.6 Million Share Offering at $5.25/Share
Get Alerts TSRX Hot Sheet
Join SI Premium – FREE
Trius Therapeutics, Inc. (Nasdaq: TSRX) today announced the pricing of an underwritten public offering of 8,600,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to Trius from this offering are expected to be approximately $45.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering is expected to close on or about January 31, 2012, subject to customary closing conditions.
Citigroup and Piper Jaffray & Co. are acting as joint book-running managers and Canaccord Genuity Inc. and Ladenburg Thalmann & Co. Inc. are acting as co-managers in the offering.
Citigroup and Piper Jaffray & Co. are acting as joint book-running managers and Canaccord Genuity Inc. and Ladenburg Thalmann & Co. Inc. are acting as co-managers in the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ReconAfrica upsizes bought-deal offering to C$19M for drilling program
- Phreesia Inc. (PHR) files mixed shelf
- Polyrizon launches $4M registered direct offering and private placement
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
Piper Jaffray, Citi, Ladenburg Thalmann Financial ServicesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share